Search Results

1-9 of 9 results for subject:Patients

Show detailed: On Off

Results: 10 20 50 100

Sort by: Newest first Oldest first

My Lords, I declare an interest in that my wife is director of Nuffield Health, the independent healthcare charity. I very much agreed with the speech of the Minister when he said that the biggest challenge that the NHS currently faces is how to improve patient care against a background...

Member

Lord Hutton of Furness (Labour)

Type

Proceeding contributions

Date

11 October 2011

Reference

730 c1568-70

House

House of Lords

Dept of Health

To ask the Secretary of State for Health, what research he has commissioned into the information on which patients would want to base their choices for elective surgery; and what steps he is taking to provide this information (a) through primary care trusts, (b) through strategic health authorities and (c)...

Asked by

Lord Lansley (Conservative)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

21 February 2005

Reference

210826; 431 c311W;431 c310-1W

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, what research his Department has commissioned regarding the complication rates following elective surgery paid for by the NHS and carried out in (a) NHS hospitals and (b) private hospitals.

Asked by

Rob Marris (Labour)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

10 February 2005

Reference

211698; 430 c1692W

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, if he will make a statement on the amount of fraud in the NHS; and what research his Department has commissioned to estimate the level of unidentified fraud in the NHS. - Including table.

Asked by

Paul Burstow (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Tabled on

12 December 2003

For answer on

18 December 2003

Answered on

18 December 2003

Mr. Burstow: To ask the Secretary of State for Health if he will make a statement on the amount of fraud in the NHS; and what research his Department has commissioned to estimate the level of unidentified fraud in the NHS. [144591] Mr. Hutton: The National Health Service Counter Fraud and Security Management Service (NHS CFSMS) has an on-going programme of highly accurate risk measurement exercises--accurate to plus or minus 1 per cent.--designed to reveal levels of losses and, through repeated exercises, reductions in such losses, where they take place. Phase one of these exercises concentrated on patient fraud. The tables show the results. £ million _________________________________________________________________________________________________. Year data selected Fraud losses Pharmaceutical patient fraud 1998-99 117 1999-2000 69 Dental patient fraud 1999-2000 40.3 2000-01 30 Optical patient fraud 1999-2000 13.25 2001-02 10.17 _________________________________________________________________________________________________. A statistically valid sample of those prescriptions prescribed during March 2003 has been taken and a further measurement exercise has been completed. Further reductions in pharmaceutical patient fraud are anticipated and figures will be produced later this month. Phase two of the programme is now focussing on contractor fraud within the NHS. As the measurement programme extends, it will enable NHS CFSMS to accurately assess the totality of NHS fraud. Total patient fraud losses have reduced from approximately £170 million to £109.17 million per year, a reduction of 36 per cent. since the creation of NHS CFSin 1998. Fraud in the NHS is not acceptable. It deprives the NHS of the resources needed for the delivery of patient care and the continuing improvement of frontline services.

Date

18 December 2003

Reference

144591; 415 c1121-2W

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, what research he has commissioned on the extent to which patients suffer deterioration in their disease prior to having an operation in (a) the United Kingdom, (b) Europe and (c) the United States.

Asked by

Andrew Rosindell (Conservative)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

18 December 2003

Reference

143438; 415 c1129-30W

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, what research his Department has commissioned into the (a) extent and (b) cost of health tourism in England; and if he will make a statement.

Asked by

Paul Burstow (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

20 November 2003

Reference

413 c1384W;413 c1380W; 139579

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, what his assessment is of the pilot scheme to send NHS patients for treatment in continental Europe; and when he plans to extend the availability of treatment in continental European hospitals of all NHS patients. Includes ref to report by York University...

Asked by

Tim Loughton (Conservative)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

20 January 2003

Reference

89931; 398 c137-8W;398 c138-9W

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, what assessment he has made of the psychological problems suffered by cancer patients; and if he will make a statement. - Inc ref to Policy Framework for Commissioning Cancer Services published by the Department and the series Improving Outcomes in Cancer published...

Asked by

Paul Marsden (Labour)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

6 July 1999

Reference

89097; 334 c491W

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, what ethical guidelines are given to government-supported medical researchers into the Alzheimer's drug Aricept about administering placebos to patients who could benefit from the drug.

Asked by

Vincent Cable (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Tabled on

11 May 1999

For answer on

20 May 1999

Answered on

20 May 1999

Dr. Cable: To ask the Secretary of State for Health what ethical guidelines are given to Government- supported medical researchers into the Alzheimer's drug Aricept about administering placebos to patients who could benefit from the drug. [84261] Mr. Hutton: All research involving patients and supported by the Department, the National Health Service or the Medical Research Council is required to obtain ethical approval from the appropriate research ethics committee(s). Scientific review mechanisms also consider ethical aspects of research, including the appropriateness of randomisation and other study designs, and the use of placebos. Guidance on research ethics is provided in the Department's Guidance for Local Research Ethics Committees and for Mulitcentre Research Ethics Committees, in conjunction with: the Royal College of Physicians' "Guidelines on the Practice of Ethics Committees in Medical Research involving Human Subjects"; and the Medical Research Council's "Guidelines for Good Practice in Clinical Trials". Copies of these will be placed in the Library. The AD2000 trial of Aricept is being supported through the NHS research and development programme. The protocol allows for patients to be randomly assigned to Aricept or a placebo when there is uncertainty (on the basis of the known effects of Aricept and the characteristics of the patient), as to whether or not Aricept would offer the patient any overall benefit. The trial has been approved by the Regional Multi-Centre Research Ethics committee and the Local Research Ethics Committee for each particular centre at which the trial is being conducted.

Date

20 May 1999

Reference

84261; 331 c421-2W

House

House of Commons

Librarians' tools

Type

House

Session

Year

Department

Member

Primary member

Answering member

Legislative stage

Legislation

Subject

Publisher